Announcements
- RAPT Therapeutics Reports First Quarter 2024 Financial Results
- RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
- RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
- RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
- RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
- RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
- RAPT Therapeutics Reports Third Quarter 2023 Financial Results
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.74 |
---|---|
High | 3.86 |
Low | 3.72 |
Bid | 3.66 |
Offer | 3.92 |
Previous close | 3.70 |
Average volume | 1.72k |
---|---|
Shares outstanding | 34.80m |
Free float | 32.02m |
P/E (TTM) | -- |
Market cap | 139.20m USD |
EPS (TTM) | -3.07 USD |
Data delayed at least 15 minutes, as of May 15 2024 18:37 BST.
More ▼